Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

Summary

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)

Timeline

Start

2016-05-01

Primary completion

2018-05-04

Completion

2018-05-04

Outcome

Outcome not reported

Stopped (Business): “Strategic Reasons”

Drugs

Indications